TABLE 2

The Risk of Idiopathic Thrombocytopenic Purpura in the 1 to 42 Days After Vaccination, for Vaccines Routinely Administered During Childhood and Adolescencea

Vaccine (age group)IRR95% CIPExposed Cases, nUnexposed Cases, n
6 wk to 11 mo2
 Hib0.530.141.94.33310
 RVb10
 DTaP07
 IPV07
 HBV07
 PCV0.580.152.18.4239
6 to 23 mo
 TIV2.690.818.88.1157
12 to 19 mo
 MMR5.481.6118.64.00665
 MMRV2.870.7810.56.1146
 DTaP10.214.81.9928
 Hib0.750.163.63.7229
 HBV02
 PCV0.720.143.97.7028
12 to 23 mo
 VAR08
 Hep A0.220.031.82.16111
2 to 6 y
 TIV1.860.418.38.4237
 Hep A1.140.343.86.83427
4 to 6 y
 MMR3.060.4222.30.2727
 MMRV05
 VAR4.390.4641.65.2015
 DTaP2.570.5312.37.24212
 IPV1.370.238.32.73212
7 to 17 y
 Hep A23.143.59149.30.00123
 TIV5.950.5465.96.1522
11 to 17 y
 VAR12.141.10133.96.0412
 MMR01
 HPV9.710.87108.92.0712
 MCV6.020.6456.18.1214
 Tdap20.293.12131.83.00223
  • a For vaccines other than MMR and MMRV, relative risks are shown only for vaccines when not given in conjunction with MMR or MMRV; LAIV is not shown, because there are no vaccine-exposed cases in any age category.

  • b Vaccines for which there are either no exposed or unexposed cases will have no IRR or CI reported.